Company / R&D Expense
PROTHENA CORP PUBLIC LTD CO R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$220.6M
FY2025
5-year range
$50.8M / $220.6M
FY2021-FY2025
Trend
+62.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 4 consecutive years, from $51M in FY2021 to $221M in FY2025.
Based on SEC 10-K filings.
$221M in FY2025 with a 5-year CAGR of +16.9%.
Improved from $82M to $221M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +43.3%
- 5-Year CAGR
- +16.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- PROTHENA CORP PUBLIC LTD CO's r&d expense has grown for 4 consecutive years.
- 5-year CAGR of +16.9%, indicating consistent growth.
- In FY2025, r&d expense increased 62.7% year-over-year.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $220.6M | +62.7% |
| FY2024 | $135.6M | +64.7% |
| FY2023 | $82.3M | +9.9% |
| FY2022 | $74.9M | +47.3% |
| FY2021 | $50.8M | -49.8% |
| FY2020 | $101.2M | -24.8% |
| FY2019 | $134.5M | +12.6% |
| FY2018 | $119.5M | +104.5% |
| FY2017 | $58.4M | +52.0% |
| FY2016 | $38.5M | +47.6% |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 28, 2026